​

CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

OverviewForecastRevenueFinancialsChart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 53.48% institutional investors, 5.90% insiders, and 40.62% retail investors. Ark investment management is the largest institutional shareholder, holding 12.58% of CRSP shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 7.64% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCRISPR Therapeutics53.48%5.90%40.62%
SectorHealthcare Stocks 35.42%11.83%52.76%
IndustryBiotech Stocks 35.46%11.78%52.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management11.31M12.58%$538.19M
Blackrock funding, inc. /de7.68M8.54%$365.34M
Orbis allan gray6.11M6.79%$290.46M
Capital world investors4.73M5.25%$224.77M
State street3.98M4.43%$189.45M
Gsk3.22M3.58%$153.21M
Blackrock2.78M3.40%$150.03M
T. rowe price investment management2.95M3.28%$140.46M
Geode capital management2.38M2.64%$113.10M
Vanguard group2.27M2.48%$118.95M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Gsk3.22M25.57%$153.21M
Sr one capital management, lp2.04M10.59%$96.98M
Spear rsc165.00K6.29%$8.91M
Versant venture management148.83K5.01%$7.08M
Ark investment management11.31M4.19%$538.19M
Nea management company1.06M2.86%$50.36M
Ecor1 capital1.39M2.80%$66.09M
Green alpha advisors57.02K2.67%$2.71M
Contrarius investment management685.72K2.32%$37.04M
Eagle health investments lp197.00K1.87%$10.64M

Top Buyers

HolderShares% AssetsChange
Capital world investors4.73M0.03%4.73M
Two sigma investments, lp1.48M0.06%1.01M
Ark investment management11.31M4.19%791.57K
Vanguard fiduciary trust542.68K0.01%542.68K
Norges bank490.21K0.00%490.21K

Top Sellers

HolderShares% AssetsChange
Capital investors1.19M0.01%-4.71M
Two sigma advisers, lp572.97K0.07%-771.73K
Ubs group1.76M0.01%-761.61K
Baker bros. advisors lp---654.10K
Farallon capital management---530.00K

New Positions

HolderShares% AssetsChangeValue
Capital world investors4.73M0.03%4.73M$224.77M
Vanguard fiduciary trust542.68K0.01%542.68K$25.82M
Norges bank490.21K0.00%490.21K$25.71M
Affinity asset advisors150.00K0.37%150.00K$7.14M
Exoduspoint capital management, lp135.13K0.05%135.13K$6.43M

Sold Out

HolderChange
Impact partnership wealth-1.00
Tortoise investment management-1.00
Activest wealth management-1.00
Carolina wealth advisors-1.00
Frazier financial advisors-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026387-25.00%48,093,713-37.13%530.74%183-27.09%90-31.82%
Dec 31, 2025430-10.60%67,314,484-6.81%731.07%208-7.96%108-11.48%
Sep 30, 2025461-2.12%71,905,056-0.80%821.19%220-6.78%11715.84%
Jun 30, 20254579.33%72,312,35012.69%831.49%22831.03%101-2.88%
Mar 31, 202516-96.30%3,317,986-94.86%30.07%8-95.58%3-97.52%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite7.33M7.64%99.89K
ARK Innovation ETF6.17M6.40%-450.25K
iShares Russell 2000 ETF2.15M2.23%18.09K
ARK Genomic Revolution ETF2.10M2.18%89.00K
ARK Genomic Revolution1.99M2.08%73.66K
American Funds New Perspective A1.94M2.03%-
Capital Group New Perspective Comp1.94M2.02%-
State Street® SPDR® S&P® Biotech ETF1.89M1.96%-18.73K
American Funds SMALLCAP World A1.65M1.72%-
SPDR® S&P Biotech ETF1.40M1.53%3.11K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 23, 2026KASINGER JAMES R. General Counsel and SecretarySell$148.85K
Mar 23, 2026Kulkarni Samarth Chief Executive OfficerSell$468.74K
Mar 23, 2026Prasad Raju Chief Financial OfficerSell$173.46K
Mar 16, 2026Patel Naimish Chief Medical OfficerSell$152.02K
Mar 16, 2026Prasad Raju Chief Financial OfficerSell$282.22K

Insider Transactions Trends

DateBuySell
2026 Q1-19
2025 Q4-6
2025 Q341
2025 Q2-1
2025 Q1117

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 53.48%, followed by 5.90% insiders and 40.62% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 35.46%, which CRISPR Therapeutics exceeds.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (11.31M shares, 12.58%), Blackrock funding, inc. /de (7.68M shares, 8.54%), and Orbis allan gray (6.11M shares, 6.79%). Together, they hold 27.91% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Gsk is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 25.57% of its assets in 3.22M CRISPR Therapeutics shares, valued at 153.21M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of CRISPR Therapeutics shares, with 7.64% of its total shares outstanding invested in 7.33M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools